SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies will be
presenting at the 2018 Cantor Global Healthcare Conference in
New York on Monday, October 1 at 3:30
p.m. ET/12:30 p.m. PT. Dr.
Helen Torley, president and chief
executive officer, will provide a corporate overview.
A live audio webcast of the presentation will be available in
the "Investors" section of Halozyme's website at www.halozyme.com
with an archived replay available for 90 days following the
event.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug
pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor in animal
models. PEGPH20 is currently in development for the treatment of
several cancers and has the potential to be used in combination
with different types of cancer therapies. In addition to its
proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical companies
including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly,
Bristol-Myers Squibb and Alexion for its ENHANZE® drug
delivery technology. Halozyme is headquartered in San Diego. For more information visit
www.halozyme.com.
Contacts:
Robert H.
Uhl
Managing Director
Westwicke Partners, LLC
858-356-5932
robert.uhl@westwicke.com
Laurie Stelzer
858-704-8222
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-participate-in-upcoming-investor-conference-300716456.html
SOURCE Halozyme Therapeutics, Inc.